TCP
HRTX icon

Tourbillon Capital Partners’s Heron Therapeutics HRTX Stock Holding History

Tourbillon Capital Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-850,000
Closed -$11.8M – 62
2017
Q2 		$11.8M Buy
850,000
+440,000
+107% +$6.37M 0.23% 58
2017
Q1 		$6.15M Buy
+410,000
New +$5.67M 0.16% 53

Other funds holding HRTX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Tourbillon Capital Partners's HRTX Position: Q3 2017 in Review

Tourbillon Capital Partners sold out of Heron Therapeutics (HRTX) in Q3 2017, closing a stake of 850,000 shares — an estimated $11.8M sold.

Tourbillon Capital Partners first reported a position in HRTX in Q1 2017 and held it in 2 quarters. The position peaked at $11.8M in Q2 2017. 104 funds tracked by Wall St. Rank hold HRTX as of Q3 2017.

  • Tourbillon Capital Partners reported no remaining Heron Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Tourbillon Capital Partners sold 850,000 Heron Therapeutics shares in Q3 2017, an estimated $11.8M.
  • Tourbillon Capital Partners first reported a position in Heron Therapeutics in Q1 2017 and held it in 2 quarters.
  • Tourbillon Capital Partners's Heron Therapeutics position peaked at $11.8M in Q2 2017.
  • 104 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2017.

Based on Tourbillon Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.